Aspirin just as effective and safer compared to dual-antiplatelet therapy (DATP)

I decided to post this study given the avalanche of anti-aspirin articles lately in media, including in regards to aspirin’s use for prevention of cardiovascular events. This is far from the first study that find aspirin to be just as effective and with fewer serious die effects compared to DATP, which usually includes at least one patented anticoagulant. Hopefully, mainstream media won’t ignore this study as they ignored all the other ones showing aspirin is truly a wonder drug when it comes to cardiovascular disease, and that the bleeding risks doctors scare patients with are nothing but paid, coordinated campaign of F.U.D by Big Pharma companies peddling DATP drugs.

https://www.miragenews.com/aspirin-alone-matches-dual-therapy-post-cabg-1528218/

“…The 2,201 patients included had a mean age of 66 years and 14.4% were women. The primary endpoint of MACE occurred in a similar proportion of patients in each group: 4.8% of patients in the DAPT group and 4.6% in the aspirin only group (hazard ratio [HR] 1.09; 95% confidence interval [CI] 0.74 to 1.60; log rank p=0.77). Major bleeding was more frequent in the DAPT group (4.9% vs. 2.0%; HR 2.50; 95% CI 1.52 to 4.11). A key secondary endpoint of net adverse clinical events (the primary endpoint plus major bleeding) was higher in the DAPT group than in the aspirin group (9.1% vs. 6.4%; HR 1.45; 95% CI 1.07 to 1.97). A total of 0.7% of patients with DAPT and 0.2% with aspirin only died during the first year after randomisation (HR 4.01; 95% CI 0.85 to 18.9). Concluding, Professor Jeppsson said: “Our 12-month data do not support the use of DAPT over aspirin alone in ACS patients after CABG, given the lack of improvement in MACE and the increased risk of major bleeding. However, further long-term follow-up is needed.”

 

 

Author: haidut